<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04875195</url>
  </required_header>
  <id_info>
    <org_study_id>3475-B68</org_study_id>
    <secondary_id>2020-005609-20</secondary_id>
    <secondary_id>MK-3475-B68</secondary_id>
    <nct_id>NCT04875195</nct_id>
  </id_info>
  <brief_title>A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)</brief_title>
  <official_title>A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate the objective response rate (ORR), by&#xD;
      cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification&#xD;
      criteria 2014 in participants treated with pembrolizumab Q6W.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">January 25, 2027</completion_date>
  <primary_completion_date type="Anticipated">April 19, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) Percentage of Participants with Complete Response (CR) or Partial Response (PR)</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>ORR by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with pembrolizumab Q6W. CR is the complete radiologic response. PR is a partial response, &gt;=50% decrease in sum of the product of the perpendicular diameters for multiple lesions for up to 6 target measurable nodes and extranodal sites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) Time from First Documented Evidence of CR or PR Until Disease Progression or Death Due to any Cause, Whichever Occurs First</measure>
    <time_frame>Up to approximately 40 months</time_frame>
    <description>DOR, the time from first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) of Pembrolizumab</measure>
    <time_frame>Predose 0-4 hours on Cycle 1 (every cycle is 6 weeks), Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 and end of infusion on Cycle 1 Day 1 and Cycle 4 Day 1, and anytime on Cycle 1 Day 22 and Cycle 4 Day 22</time_frame>
    <description>Area under the plasma-time curve.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration (Cmax) of Pembrolizumab</measure>
    <time_frame>Predose 0-4 hours on Cycle 1 (every cycle is 6 weeks), Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 and end of infusion on Cycle 1 Day 1 and Cycle 4 Day 1, and anytime on Cycle 1 Day 22 and Cycle 4 Day 22</time_frame>
    <description>Cmax is a measure of the maximum amount of drug in the plasma after the dose is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration (Cmin) of Pembrolizumab</measure>
    <time_frame>Predose 0-4 hours on Cycle 1 (every cycle is 6 weeks), Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 and end of infusion on Cycle 1 Day 1 and Cycle 4 Day 1, and anytime on Cycle 1 Day 22 and Cycle 4 Day 22</time_frame>
    <description>Cmin is a measure of the minimum amount of drug in the plasma after the dose is given.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug Antibody Levels (ADA) for Pembrolizumab</measure>
    <time_frame>Predose 0-4 hours on Cycle 1 (every cycle is 6 weeks), Cycle 1 Day 1, Cycle 2 Day 1, Cycle 4 Day 1, and Cycle 5 Day 1 and end of infusion on Cycle 1 Day 1 and Cycle 4 Day 1, and anytime on Cycle 1 Day 22 and Cycle 4 Day 22</time_frame>
    <description>ADA response to pembrolizumab at the beginning of each of the first 5 cycles will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to approximately 30 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Discontinued Study Treatment Due to AEs</measure>
    <time_frame>Up to approximately 27 months</time_frame>
    <description>An adverse event (AE) is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Hodgkin's Lymphoma</condition>
  <condition>Primary Mediastinal Large B-cell Lymphoma (PMBCL)</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pembrolizumab (MK-3475), 400 mg, Q6W, intravenous (IV) infusion, Day 1 then Q6W up to 18 doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>MK-3475</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a histologically confirmed diagnosis of cHL or PMBCL, according to the World&#xD;
             Health Organization (WHO) classification [Swerdlow, S. H., et al 2008].&#xD;
&#xD;
          -  Has radiographically measurable cHL or PMBCL disease as per Lugano classification with&#xD;
             at least 1 nodal lesion (which has not been previously radiated) that is &gt;15 mm in&#xD;
             long axis, regardless of the length of the short axis, AND/OR extranodal lesion of &gt;10&#xD;
             mm in long and short axis.&#xD;
&#xD;
        PMBCL-Specific Disease Characteristics:&#xD;
&#xD;
          -  Have relapsed or refractory PMBCL and:&#xD;
&#xD;
          -  Have relapsed after auto-stem cell transplant (SCT) or have failed to achieve a CR or&#xD;
             PR within 60 days of auto-SCT. Participants may have received intervening therapy&#xD;
             after auto-SCT for relapsed or refractory disease, in which case they must have&#xD;
             relapsed after or be refractory to their last treatment.&#xD;
&#xD;
        OR&#xD;
&#xD;
        - For participants who are ineligible for auto-SCT, have received at least ≥2 lines of&#xD;
        prior therapy and have failed to respond to or relapsed after their last line of treatment.&#xD;
        At least 1 of the prior lines of therapy must contain a rituximab-based regimen.&#xD;
&#xD;
        Note: Participants should not need urgent cytoreductive therapy.&#xD;
&#xD;
          -  Relapsed Disease: disease progression after achieving an overall response of PR or CR&#xD;
             in response to the most recent therapy&#xD;
&#xD;
          -  Refractory Disease: failure to achieve CR or PR to the most recent therapy.&#xD;
&#xD;
        cHL-Specific Disease Characteristics:&#xD;
&#xD;
          -  Have relapsed or refractory cHL and:&#xD;
&#xD;
          -  Have relapsed during their last cHL regimen after receiving at least 2 cycles of&#xD;
             therapy or within 12 months after completing the last regimen for cHL.&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Have received at least ≥1 line of prior multiagent therapy with/without brentuximab&#xD;
             vedotin (excluding radiation) or auto-SCT for cHL and have failed to respond to or&#xD;
             relapsed after their last line of treatment.&#xD;
&#xD;
               -  Relapsed Disease: disease progression after achieving an overall response of PR&#xD;
                  or CR to the most recent therapy.&#xD;
&#xD;
               -  Refractory Disease: failure to achieve CR or PR to the most recent therapy.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies:&#xD;
&#xD;
          -  Is not a woman of child bearing potential (WOCBP). OR&#xD;
&#xD;
          -  Is a WOCBP and using a contraceptive method that is highly effective (with a failure&#xD;
             rate of &lt;1% per year), or be abstinent from heterosexual intercourse as their&#xD;
             preferred and usual lifestyle (abstinent on a long-term and persistent basis), for at&#xD;
             least 120 days after the last dose of study intervention.&#xD;
&#xD;
          -  Submit an evaluable core lymph node biopsy for biomarker analysis from an archival&#xD;
             (&gt;60 days) or newly obtained (within 30 days) core or incisional biopsy at Screening&#xD;
             which was not previously irradiated. Note: If no archival tissue is available, 2 new&#xD;
             fresh core needle samples are required.&#xD;
&#xD;
          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.&#xD;
&#xD;
          -  Life expectancy &gt;3 months.&#xD;
&#xD;
          -  Adequate organ function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic&#xD;
             SCT within the last 5 years.&#xD;
&#xD;
          -  Has clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt;6 months prior to enrollment), myocardial infarction (&lt;6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (New York Heart&#xD;
             Association Classification Class ≥II), or serious cardiac arrhythmia requiring&#xD;
             medication.&#xD;
&#xD;
          -  Has pericardial effusion or clinically significant pleural effusion.&#xD;
&#xD;
          -  Has a history of a second malignancy, unless potentially curative treatment has been&#xD;
             completed with no evidence of malignancy for 2 years. Note: The time requirement does&#xD;
             not apply to participants who underwent successful definitive resection of basal cell&#xD;
             carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder&#xD;
             cancer, in situ cervical cancer, or other in situ cancers.&#xD;
&#xD;
          -  Is receiving systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone&#xD;
             equivalent) &lt;3 days prior to the first dose of study intervention. Note: Participants&#xD;
             who receive daily steroid replacement therapy are an exception.&#xD;
&#xD;
          -  Has received prior monoclonal antibody within 4 weeks prior to first dose of study&#xD;
             intervention or has not recovered (i.e., ≤Grade 1 or at baseline) from adverse event&#xD;
             (AEs) due to agents administered more than 4 weeks earlier.&#xD;
&#xD;
          -  Has received prior therapy with an anti-programmed cell death 1 protein (PD-1),&#xD;
             anti-programmed cell death ligand 1 (PD-L1), or anti-programmed cell death ligand 2&#xD;
             (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell&#xD;
             receptor (e.g., CTLA-4, OX-40, CD137).&#xD;
&#xD;
          -  Has received prior chimeric antigen receptor T-cell (CAR-T) therapy.&#xD;
&#xD;
          -  Has received prior systemic anticancer therapy, or radiotherapy, including&#xD;
             investigational agents within 4 weeks prior to the first dose of study intervention.&#xD;
             Note: If the participant had a major operation, the participant must have recovered&#xD;
             adequately from the procedure and/or any complications from the operation before&#xD;
             starting study intervention.&#xD;
&#xD;
          -  Has received prior radiotherapy within 2 weeks of start of study intervention.&#xD;
             Participants must have recovered from all radiation-related toxicities, not require&#xD;
             corticosteroids, and not have had radiation pneumonitis.&#xD;
&#xD;
          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of&#xD;
             study drug.&#xD;
&#xD;
          -  Is currently participating in or has participated in a study of an investigational&#xD;
             agent or has used an investigational device within 4 weeks before the first dose of&#xD;
             study intervention.&#xD;
&#xD;
          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy&#xD;
             (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of&#xD;
             immunosuppressive therapy within 7 days prior to the first dose of study medication.&#xD;
&#xD;
          -  Has known active central nervous system (CNS) lymphoma involvement or active CNS&#xD;
             involvement by lymphoma.&#xD;
&#xD;
          -  Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.&#xD;
&#xD;
          -  Has an active autoimmune disease that has required systemic treatment in past 2 years&#xD;
             (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive&#xD;
             drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid&#xD;
             replacement therapy for adrenal or pituitary insufficiency) is not considered a form&#xD;
             of systemic treatment and is allowed.&#xD;
&#xD;
          -  Has a history of (noninfectious) pneumonitis/interstitial lung disease that required&#xD;
             steroids or has current pneumonitis/interstitial lung disease.&#xD;
&#xD;
          -  Has an active infection requiring systemic therapy.&#xD;
&#xD;
          -  Has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is&#xD;
             required unless mandated by local health authority.&#xD;
&#xD;
          -  Has a known history of Hepatitis B (defined as hepatitis B surface antigen (HBsAg)&#xD;
             reactive) or known active Hepatitis C virus infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
    <email>Trialsites@merck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lundquist Institute for Biomedical Innovation at Harbor-UCLA-Hematology and Medical Oncology ( Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>424-201-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tulane Medical Center ( Site 0110)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>504-988-6770</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anne Arundel Medical Center-Anne Arundel Oncology and Hematology ( Site 0125)</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>443-481-5800</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0302)</name>
      <address>
        <city>Brno</city>
        <state>Brno-mesto</state>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>420532233642</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Kralovske Vinohrady-Interni hematologicka klinika ( Site 0303)</name>
      <address>
        <city>Prague</city>
        <state>Praha 10</state>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420 267 163 554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove-IV. interni hematologicka klinika ( Site 0304)</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+420 267 163 554</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy ( Site 0402)</name>
      <address>
        <city>Villejuif</city>
        <state>Val-de-Marne</state>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>33142114507</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori IRCCS Fondazione Pascale ( Site 0503)</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>390815903382</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia MCM Krakow ( Site 0064)</name>
      <address>
        <city>Krakow</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+48 602338290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0063)</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>58 584 43 40</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny im. Przemienienia Panskiego Uniwersytetu M-Oddzial Hematologii i Transplantacji S</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>618549356</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The National Medico-Surgical Center N.I. Pirogov ( Site 0801)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>105203</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>74956037217</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow City Clinical Hospital S.P. Botkin ( Site 0803)</name>
      <address>
        <city>Moscow</city>
        <state>Moskva</state>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>79165720644</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Almazov National Medical Research Centre ( Site 0807)</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Sankt-Peterburg</state>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+78127023700</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Netcare Pretoria East Hospital-Albert Alberts Stem Cell Transplant Centre ( Site 0902)</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>0044</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27129932555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wits Clinical Research ( Site 0904)</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>1864</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+27119339589</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Groote Schuur Hospital ( Site 0906)</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7925</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>27818502790</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medicine of Faculty ( Site 1105)</name>
      <address>
        <city>Bornova</city>
        <state>Izmir</state>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>+905325566128</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Department of Hematology, Clinical Research Unit ( Site 1101)</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CNPE Regional Center of Oncology ( Site 1305)</name>
      <address>
        <city>Kharkiv</city>
        <state>Kharkivska Oblast</state>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380573151591</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute ( Site 1303)</name>
      <address>
        <city>Kyiv</city>
        <state>Kyivska Oblast</state>
        <zip>03022</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>380442579315</phone>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>France</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>May 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD1</keyword>
  <keyword>PD-1</keyword>
  <keyword>PDL1</keyword>
  <keyword>PD-L1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

